Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Double-Masked, Randomised, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy OF Non-Proliferative Type (NPDR)

NCT06770933 is registered in ClinicalTrials.gov with Vantage Biosciences Ltd as lead sponsor.

NCT NCT06770933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06770933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Double-Masked, Randomised, Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 in Diabetic Retinopathy OF Non-Proliferative Type (NPDR)
Lead sponsor
Vantage Biosciences Ltd
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 11, 2025
Completion date
October 31, 2027
Enrollment
100 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic retinopathy, npdr - non proliferative diabetic retinopathy